UBS Group’s Clearmind Medicine CMND Stock Holding History

UBS Group’s Portfolio CMND Stock Details CMND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Hold	0	–	-$1	–	10505
2026 Q1	–	Hold	0	–	–	–	10383
2024 Q4	–	Sell	-44	Closed	-$172K	–	9982
2024 Q3	$172K	Buy	+44	New	+$200K	﹤0.01%	5981
2023 Q2	–	Hold	0	–	-$3.15K	–	9002
2023 Q1	–	Hold	0	–	–	–	8369
2022 Q4	–	Hold	0	–	–	–	9121

Other funds holding CMND

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's CMND Position: Q2 2026 in Review

UBS Group held its Clearmind Medicine (CMND) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #10505.

UBS Group first reported a position in CMND in Q3 2024 and has held it in 1 quarter since. The position peaked at $172K in Q3 2024. 5 funds tracked by Wall St. Rank hold CMND as of Q2 2026.

UBS Group held 0 shares of Clearmind Medicine worth $0 as of Q2 2026.
UBS Group left its Clearmind Medicine share count unchanged in Q2 2026.
Clearmind Medicine made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10505 holding.
UBS Group first reported a position in Clearmind Medicine in Q3 2024 and has held it in 1 quarter since.
UBS Group's Clearmind Medicine position peaked at $172K in Q3 2024.
5 funds tracked by Wall St. Rank held Clearmind Medicine as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.